Potential in MRI and PET-CT Lymphoma Cancer Characterization

April 8, 2013

Utilizing magnetic resonance imaging (MRI) in disease evaluation and positron emission computed tomography-computed tomography (PET-CT) imaging in therapy response assessment could optimize patient outcome in lymphoma cancer.

“MRI gives us more information and is probably the most important imaging technique in assessing disease activity in myeloma,” said Dr. Jens Hillengass, a physician scientist from the German Cancer Research Center (Heidelberg, Germany) who presented his findings on March 9, 2013, during the State of the Art symposium at the European Congress of Radiology (ECR), held in Vienna (Austria).